As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.
Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...
Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback